Nine Square Therapeutics: Funding, Investors & Team (Sep 2026)
Nine Square Therapeutics, based in New York, is a company established in 2020 that focuses on the development of small-molecule treatments for degenerative movement disorders like Parkinson's disease and ALS, as well as non-degenerative disorders like essential tremor and dyskinesias. The company employs a combination of computational chemistry, biophysics, and computational biology, along with machine-learning-powered cell profiling platforms, to identify potential targets, optimize chemical compounds, and stratify patients.
Nine Square Therapeutics has raised $4.5M across 1 funding round on record, the most recent an undisclosed round of $4.5M announced in Sep 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nine Square Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Nine Square Therapeutics Funding Rounds
Nine Square Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Nine Square Therapeutics Funding Compared to Other Biotechnology Startups
Nine Square Therapeutics' latest round of $4.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nine Square Therapeutics in Biotechnology and New York
Companies Similar to Nine Square Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Nine Square Therapeutics Funding FAQs
What does Nine Square Therapeutics do?
Nine Square Therapeutics, based in New York, is a company established in 2020 that focuses on the development of small-molecule treatments for degenerative movement disorders like Parkinson's disease and ALS, as well as non-degenerative disorders like essential tremor and dyskinesias. The company employs a combination of computational chemistry, biophysics, and computational biology, along with machine-learning-powered cell profiling platforms, to identify potential targets, optimize chemical compounds, and stratify patients.
How much funding has Nine Square Therapeutics raised?
Nine Square Therapeutics has raised $4.5M across 1 round on record. The most recent is an undisclosed round of $4.5M announced in Sep 2023.
When did Nine Square Therapeutics last raise funding?
Nine Square Therapeutics' most recent funding round on record is an undisclosed round of $4.5M, announced in Sep 2023.
Who founded Nine Square Therapeutics?
FundedIQ lists Steven Altschuler (Founder) at Nine Square Therapeutics.
Where is Nine Square Therapeutics headquartered?
Nine Square Therapeutics is based in New York, United States.
How many employees does Nine Square Therapeutics have?
Nine Square Therapeutics is in the 101-250 employee band.
How does Nine Square Therapeutics' funding compare to other Biotechnology startups?
Nine Square Therapeutics' latest round of $4.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Nine Square Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nine Square Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.